International stocks trading in New York closed mostly higher on Monday.
The S&P/BNY Mellon index of American depositary receipts edged up 0.1% to 161.18. The Asian index rose 0.4% to 217.60. And the emerging-markets index increased 0.2% to 360.56.
The European index eased 0.1% to 142.32. And the Latin American index declined 0.1% to 186.72.
Eni SpA was among those whose ADRs traded actively.
AstraZeneca PLC's antibody cocktail AZD7442 could help nonhospitalized patients with mild to moderate Covid-19 avoid more severe illness, the drugmaker says in summarized, preliminary trial results. Full trial results haven't been reviewed by independent researchers or published. ADRs rose 0.3% to $60.80.
The Covid-19 vaccine from Pfizer Inc. and BioNTech SE has emerged as the world's vaccine of choice. From Latin America to the Middle East, dozens of governments are turning to the shot. Australia is now offering the vaccine, after shifting away from competitors. Turkey, the U.K. and Chile are providing the Pfizer-BioNTech vaccine to people who took other shots. BioNTech's ADRs closed down 1.2% at $243.02.
European oil stocks gain as crude prices continue to rise, with the global energy crunch fueling higher demand and inflation fears. "The recent sharp increase in energy prices has added to risks that inflation may accelerate further and remain entrenched for longer," Societe Generale analysts say. "While this trend benefits energy exporters, it may also result in slower global economic recovery, a deterioration in energy-importers' external balances and depreciating pressures in currencies." BP PLC rose 0.8% to $29.10; Eni SpA rose 0.6% to $27.61; Royal Dutch Shell PLC's Class B ADRs rose 1.3% to $47.05; and TotalEnergies SE rose 1% to $50.60.
-- WSJ Staff
(END) Dow Jones Newswires
10-11-21 1850ET
